Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(1):106–109. doi: 10.1038/bjc.1996.19

Type I and type III collagen metabolites in adult osteosarcoma patients.

T Wiklund 1, C Blomqvist 1, L Risteli 1, J Risteli 1, E Karaharju 1, I Elomaa 1
PMCID: PMC2074279  PMID: 8554970

Abstract

Three biochemical markers of collagen metabolism were measured in 39 osteosarcoma patients. The pretreatment values did not predict outcome, and the markers showed no consistent change upon development of metastases. Both the age of the patients and the multimodality therapy affected the collagen metabolites. These findings emphasise the need for cautious interpretation of tumour-associated markers.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard N., Nielsen J. L., Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol. 1994 Jul;46(3):173–178. doi: 10.1002/ajh.2830460303. [DOI] [PubMed] [Google Scholar]
  2. Bacci G., Picci P., Ferrari S., Orlandi M., Ruggieri P., Casadei R., Ferraro A., Biagini R., Battistini A. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer. 1993 Feb 15;71(4):1224–1230. doi: 10.1002/1097-0142(19930215)71:4<1224::aid-cncr2820710409>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  3. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Haukipuro K., Risteli L., Kairaluoma M. I., Risteli J. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery. 1990 Apr;107(4):381–388. [PubMed] [Google Scholar]
  5. Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995 May;71(5):1061–1064. doi: 10.1038/bjc.1995.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4. [DOI] [PubMed] [Google Scholar]
  7. Link M. P., Goorin A. M., Horowitz M., Meyer W. H., Belasco J., Baker A., Ayala A., Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991 Sep;(270):8–14. [PubMed] [Google Scholar]
  8. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  9. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  10. Risteli J., Niemi S., Trivedi P., Mäentausta O., Mowat A. P., Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988 Apr;34(4):715–718. [PubMed] [Google Scholar]
  11. Stein G. S., Lian J. B., Owen T. A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 1990 Oct;4(13):3111–3123. doi: 10.1096/fasebj.4.13.2210157. [DOI] [PubMed] [Google Scholar]
  12. Taube T., Franssila K., Risteli L., Risteli J., Elomaa I. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP). Br J Haematol. 1992 Sep;82(1):32–37. doi: 10.1111/j.1365-2141.1992.tb04590.x. [DOI] [PubMed] [Google Scholar]
  13. Wiklund T. A., Blomqvist C. P., Risteli L., Risteli J., Elomaa I. Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas. J Cancer Res Clin Oncol. 1993;119(3):160–164. doi: 10.1007/BF01229531. [DOI] [PubMed] [Google Scholar]
  14. Wiklund T. A., Elomaa I., Blomqvist C. P., Risteli L., Risteli J. Type III collagen metabolism in soft tissue sarcomas. Br J Cancer. 1992 Feb;65(2):193–196. doi: 10.1038/bjc.1992.40. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES